[6-K] Genmab A/S ADS Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Form 4 filing for Northwest Bancshares, Inc. (NWBI) discloses an open-market purchase by director Timothy M. Hunter.

• Transaction date: 08/06/2025
• Security: Northwest Bancshares common stock
• Transaction code: P (purchase)
• Shares acquired: 10,000
• Average price: $11.656 (high $11.66; low $11.65)
• Total cost: ≈ $116.6 k
• Post-transaction holding: 185,751 shares
• Ownership form: Direct

No derivative securities were reported. The filing was signed on 08/07/2025 by an attorney-in-fact on Hunter’s behalf.

Positive

• Director increased direct ownership by 10,000 shares, signaling alignment with shareholders.

Negative

• None.

Insights

Securities Analyst

TL;DR: Director bought 10k NWBI shares; modest size, mildly positive signal, limited financial impact.

Director Timothy M. Hunter increased his direct stake by 10,000 shares at $11.656, bringing his ownership to 185,751 shares. While insider buying can indicate confidence, the dollar value (~$117 k) is small relative to Northwest Bancshares’ market capitalization, so the transaction is unlikely to move fundamentals or valuation. No derivatives or sales were reported, so dilution is unaffected. Overall impact is sentiment-positive but financially immaterial.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF AUGUST 2025

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated August 7, 2025: Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: August 7, 2025

FAQ

Who conducted the insider transaction for NWBI?

Timothy M. Hunter, a director of Northwest Bancshares, Inc.

How many NWBI shares were purchased?

10,000 common shares were acquired.

What was the average purchase price of NWBI stock?

The weighted average price was $11.656 per share.

What is the director’s total NWBI shareholding after the transaction?

Post-transaction, Hunter owns 185,751 shares directly.

Were any derivative securities involved in this Form 4?

No. The filing lists no derivative transactions or holdings.